Marcio Souza, Praxis Precision Medicines CEO
January 11, 2024 11:32 AM EST
Financing

Prax­is prices $150M pub­lic stock of­fer­ing ahead of four topline neu­ro read­outs in 2024

Katherine Lewin

News Reporter

Boston-based Prax­is Pre­ci­sion Med­i­cines an­nounced Thurs­day the pric­ing of a $150 mil­lion pub­lic stock of­fer­ing, with an ex­pect­ed close date around …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

A service from the Financial Times